Hepatitis: Difference between revisions
Ifeoma Anaya (talk | contribs) No edit summary |
|||
(31 intermediate revisions by 9 users not shown) | |||
Line 7: | Line 7: | ||
==Overview== | ==Overview== | ||
[[Hepatitis, chronic autoimmune|Hepatitis]] refers to the inflammation of the liver. The etiologic agent could be infectious (almost always viral) or non-infectious. Hepatitis can be acute and self limiting or can be chronic and progress to cirrhosis or hepatocellular carcinoma (HCC). Most common causes of infectious hepatitis are viral in origin. These include hepatitis A, B, C, D and E . Non infectious causes of hepatitis include autoimmune, alcohol, drugs and toxins. Alcoholic hepatitis and and non alcoholic steatohepatitis (NASH) are the most common non-infectious types of hepatitis. | |||
The common manifestation of acute hepatitis are fever, jaundice, fatigue, abdominal pain, and hepatomegaly. Diagnosis of hepatitis is based on the clinical manifestations and laboratory findings. In rare conditions liver biopsy is required for either the diagnosis or formulating a treatment plan. | |||
==Classification== | ==Classification== | ||
Hepatitis may be classified | Hepatitis may be classified depending on the duration of the disease into the following types: | ||
*Infectious | |||
*Non-infectious | *Acute hepatitis | ||
===Infectious | *Chronic hepatitis | ||
Infectious hepatitis classified according to viral agent in to 7 major | |||
Hepatitis may also be classified on the basis of various causes into the following types: | |||
*Infectious hepatitis | |||
*Non-infectious hepatitis | |||
===Infectious Hepatitis=== | |||
Infectious hepatitis can be classified according to the causative viral agent in to 7 major categories. | |||
<br> | <br> | ||
<br> | <br> | ||
{| align="center" | {| align="center" | ||
|- | |- | ||
| | | | ||
{{familytree/start}} | {{familytree/start}} | ||
{{familytree | | | | | | | | | | | | | | | A01 | | | | | |A01='''Viral Hepatitis'''}} | {{familytree | | | | | | | | | | | | | | | A01 | | | | | |A01='''Viral Hepatitis'''}} | ||
Line 39: | Line 49: | ||
{{familytree | |,|-|-|-|v|-|-|-|v|-|-|-|+|-|-|-|v|-|-|-|v|-|-|-|v|-|-|-|.| | }} | {{familytree | |,|-|-|-|v|-|-|-|v|-|-|-|+|-|-|-|v|-|-|-|v|-|-|-|v|-|-|-|.| | }} | ||
{{familytree | |!| | | |!| | | |!| | | |!| | | |!| | | |!| | | |!| | | |!| }} | {{familytree | |!| | | |!| | | |!| | | |!| | | |!| | | |!| | | |!| | | |!| }} | ||
{{familytree | D01 | |D02| | D03 | | D04 | |D05| | D06 | | D07 | |D08| | |D01=[[Alcoholic hepatitis]]|D02=[[Non-alcoholic steatohepatitis]] ([[NASH]])|D03=[[ | {{familytree | D01 | |D02| | D03 | | D04 | |D05| | D06 | | D07 | |D08| | |D01=[[Alcoholic hepatitis]]|D02=[[Non-alcoholic steatohepatitis]] ([[NASH]])|D03=[[Alpha 1 antitrypsin deficiency]]|D04=[[Autoimmune hepatitis]]|D05=Obstructive hepatitis|D06=[[Drug induced liver injury|Drug related hepatitis]]|D07=Toxin related hepatitis|D08=Ischemic hepatitis}} | ||
{{familytree | | | | | | | | | | | | | | | | | |!| | | |!| | | |!| | | | | }} | {{familytree | | | | | | | | | | | | | | | | | |!| | | |!| | | |!| | | | | }} | ||
{{familytree |boxstyle=text-align: left; | | | | | | | | | | | | | | | | | E01 | | E02 | | E03 | | | | | |E01=•[[Gallstones]] <br>•[[Tumors]]|E02= •[[Isoniazid]]<br>•[[NSAIDs]]<br>•Beta-lactam antibiotics<br>•Sulfa-containing drugs<br>•[[HAART]]|E03=Chemicals}} | {{familytree |boxstyle=text-align: left; | | | | | | | | | | | | | | | | | E01 | | E02 | | E03 | | | | | |E01=•[[Gallstones]] <br>•[[Tumors]]|E02= •[[Isoniazid]]<br>•[[NSAIDs]]<br>•Beta-lactam antibiotics<br>•Sulfa-containing drugs<br>•[[HAART]]|E03=Chemicals}} | ||
{{familytree/end}} | {{familytree/end}} | ||
<br><br> | <br><br> | ||
==Differential diagnosis== | ==Differential diagnosis== | ||
Line 51: | Line 59: | ||
{| | {| | ||
|- style="background: #4479BA; color: #FFFFFF; text-align: center;" | |- style="background: #4479BA; color: #FFFFFF; text-align: center;" | ||
! colspan="2" rowspan="3 | ! colspan="2" rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Disease | ||
! colspan="5 | ! colspan="5" style="background:#4479BA; color: #FFFFFF;" align="center" |Clinical manifestations | ||
! colspan="3 | ! colspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Laboratory findings | ||
! rowspan="3 | ! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Additional findings | ||
|- | |- | ||
! colspan="3 | ! colspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Symptoms | ||
! colspan="2 | ! colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |Signs | ||
! rowspan="2 | ! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |Transaminitis (elevated AST and ALT) | ||
! rowspan="2 | ! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |Viral markers | ||
! rowspan="2 | ! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |Autoimmune markers | ||
|- | |- | ||
! | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Nausea & vomiting | ||
! | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Abdominal pain | ||
! | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Arthralgia | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Jaundice | |||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Hepatomegaly | |||
|- | |- | ||
| rowspan="6" style="background:#4479BA; color: #FFFFFF" |Acute viral hepatitis | | rowspan="6" style="background:#4479BA; color: #FFFFFF" |Acute viral hepatitis | ||
Line 79: | Line 87: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | --- | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | --- | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* Fecal-oral transmission | *Fecal-oral transmission | ||
* Usually acute and self limit | *Usually acute and self limit | ||
* [[Fever]] | *[[Fever]] usually present | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Hepatitis B]] | | style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Hepatitis B]] | ||
Line 93: | Line 101: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | --- | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | --- | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* Percutaneous transmission | *Percutaneous transmission most common | ||
* May cause acute hepatic failure or | *May cause acute hepatic failure or may become chronic | ||
* [[Fever]] | *[[Fever]] usually present | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Hepatitis C]] | | style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Hepatitis C]] | ||
Line 107: | Line 115: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>---</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>---</nowiki> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* Percutaneous transmission is | *Percutaneous transmission is most common | ||
* Higher rate of chronic progression | *Higher rate of chronic progression | ||
* Associated with extra hepatic manifestation such as | *Associated with extra hepatic manifestation such as [[cryoglobulinemia]] and [[membranoproliferative glomerulonephritis]] | ||
* [[Fever]] | *[[Fever]] usually present | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Hepatitis E]] | | style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Hepatitis E]] | ||
Line 122: | Line 130: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>---</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>---</nowiki> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* Fecal-oral transmission | *Fecal-oral transmission | ||
* May cause fulminant disease in | *May cause fulminant disease in pregnancy | ||
* [[Fever]] | *[[Fever]] usually present | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Cytomegalovirus infection natural history, complications and prognosis|CMV hepatitis]] | | style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Cytomegalovirus infection natural history, complications and prognosis|CMV hepatitis]] | ||
Line 135: | Line 143: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |CMV-specific immunoglobulin (Ig)M antibody | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |CMV-specific immunoglobulin (Ig)M antibody | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>--</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>--</nowiki> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |Usually manifests as mononucleosis syndrome | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
*Usually manifests as mononucleosis syndrome | |||
*[[fever]] usually present | |||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[EBV]] hepatitis | | style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[EBV]] hepatitis | ||
Line 146: | Line 156: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Antibody|Heterophile antibody test]], monospot test | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Antibody|Heterophile antibody test]], monospot test | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>--</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>--</nowiki> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |Systemic manifestations as mononucleosis syndrome | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
*Systemic manifestations as mononucleosis syndrome | |||
*Fever usually present | |||
|- | |- | ||
| colspan="2 | | colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |Autoimmune hepatitis | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>-</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>-</nowiki> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | ||
Line 157: | Line 169: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>---</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>---</nowiki> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Antinuclear antibodies|ANA]], [[Anti-SM antibody|ASMA]], anti SLA/LP, [[ANCA]], ALKM-1 antibodies | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Antinuclear antibodies|ANA]], [[Anti-SM antibody|ASMA]], anti SLA/LP, [[ANCA]], ALKM-1 antibodies | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |Liver biopsy may be required for diagnosis | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
*Liver biopsy may be required for diagnosis | |||
|- | |- | ||
| colspan="2 | | colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |Alcoholic hepatitis | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+/-</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+/-</nowiki> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | ||
Line 168: | Line 181: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | --- | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | --- | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>---</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>---</nowiki> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |History of alcohol intake | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
*History of alcohol intake | |||
|- | |- | ||
| colspan="2 | | colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |Drug induced hepatitis | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+/-</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+/-</nowiki> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | ||
Line 179: | Line 193: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>---</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>---</nowiki> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>---</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>---</nowiki> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |May cause either cholestatic or hepatocellular injury | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
*May cause either cholestatic or hepatocellular injury | |||
|} | |} | ||
==Treatment== | |||
Treatment of [[hepatitis A]] and [[hepatitis E]] is supportive as they are usually self-limited. Chronic hepatitis E is treated with the antiviral ribavirin. | |||
[[Hepatitis B|Hepatitis B infection]] is treated with pegylated interferon alfa or nucleoside analogs (entecavir, tenofovir) based on the clinical picture including ALT and HBV DNA levels and presence or absence of cirrhosis. | |||
Treatment is indicated in chronic [[Hepatitis C]] infection which is defined as the presence of detectable HCV RNA levels for 6 months. The selection of treatment regimen depends on viral genotype, presence or absence of cirrhosis and other patient factors. Some of the commonly used antiviral regimens include sofosbuvir-velpatasvir, glecaprevir-pibrentasvir and ledipasvir-sofosbuvir | |||
Acute [[hepatitis D]] has no specific treatment. For chronic hepatitis D infection, treatment is indicated with PEG interferon alfa for patients with detectable HDV RNA, elevated ALT and evidence of active liver disease. | |||
Asymptomatic patients can be monitored for development of active disease. | |||
[[Alcoholic hepatitis]] is generally treated with alcohol abstinence and supportive care in mild to moderate cases. Severe cases are treated with tapering courses of glucocorticoids. | |||
[[Autoimmune hepatitis]] is treated with glucocorticoid mono therapy or combination of glucocorticoid with azathioprine. Treatment decision is based on symptom severity, laboratory and histologic findings. | |||
==Prevention== | |||
'''Hepatitis A''' | |||
* Vaccination especially amongst high-risk individuals who were not vaccinated in childhood. These include IV drug users, Chronic liver disease patients, and Men who have sex with men (MSM). | |||
* For individuals at risk of both HAV and HBV, the combined vaccine used as a 3-does series is administered. | |||
{{WH}} | {{WH}} | ||
Line 187: | Line 223: | ||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
[[Category:Hepatology]] | [[Category:Hepatology]] | ||
[[Category: | [[Category:Disease]] | ||
[[Category:Emergency medicine]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Emergency mdicine]] | |||
[[Category:Infectious disease]] | [[Category:Infectious disease]] | ||
Latest revision as of 14:10, 6 October 2021
For patient information click here.
Hepatitis Main Page |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Seyedmahdi Pahlavani, M.D. [2], Usama Talib, BSc, MD [3]
Overview
Hepatitis refers to the inflammation of the liver. The etiologic agent could be infectious (almost always viral) or non-infectious. Hepatitis can be acute and self limiting or can be chronic and progress to cirrhosis or hepatocellular carcinoma (HCC). Most common causes of infectious hepatitis are viral in origin. These include hepatitis A, B, C, D and E . Non infectious causes of hepatitis include autoimmune, alcohol, drugs and toxins. Alcoholic hepatitis and and non alcoholic steatohepatitis (NASH) are the most common non-infectious types of hepatitis.
The common manifestation of acute hepatitis are fever, jaundice, fatigue, abdominal pain, and hepatomegaly. Diagnosis of hepatitis is based on the clinical manifestations and laboratory findings. In rare conditions liver biopsy is required for either the diagnosis or formulating a treatment plan.
Classification
Hepatitis may be classified depending on the duration of the disease into the following types:
- Acute hepatitis
- Chronic hepatitis
Hepatitis may also be classified on the basis of various causes into the following types:
- Infectious hepatitis
- Non-infectious hepatitis
Infectious Hepatitis
Infectious hepatitis can be classified according to the causative viral agent in to 7 major categories.
|
Non-Infectious Hepatitis
Non-infectious Hepatitis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Alcoholic hepatitis | Non-alcoholic steatohepatitis (NASH) | Alpha 1 antitrypsin deficiency | Autoimmune hepatitis | Obstructive hepatitis | Drug related hepatitis | Toxin related hepatitis | Ischemic hepatitis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
•Gallstones •Tumors | •Isoniazid •NSAIDs •Beta-lactam antibiotics •Sulfa-containing drugs •HAART | Chemicals | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Differential diagnosis
Hepatitis must be differentiated from other conditions that may cause fever, fatigue, nausea and vomiting, and elevated liver enzymes.
Disease | Clinical manifestations | Laboratory findings | Additional findings | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Signs | Transaminitis (elevated AST and ALT) | Viral markers | Autoimmune markers | ||||||
Nausea & vomiting | Abdominal pain | Arthralgia | Jaundice | Hepatomegaly | ||||||
Acute viral hepatitis | Hepatitis A | +++ | ++ | + | +++ | + | +++ | HAV Ab | --- |
|
Hepatitis B | +++ | ++ | ++ | +++ | + | +++ | HBs Ag, HBc Ab, HBe Ag | --- |
| |
Hepatitis C | +++ | ++ | ++ | +++ | + | +++ | HCV Ab | --- |
| |
Hepatitis E | ++ | ++ | +/- | ++ | + | +++ | HEV Ab | --- |
| |
CMV hepatitis | +/- | ++ | - | + | + | ++ | CMV-specific immunoglobulin (Ig)M antibody | -- |
| |
EBV hepatitis | +/- | ++ | - | +/- | + | ++ | Heterophile antibody test, monospot test | -- |
| |
Autoimmune hepatitis | - | + | +/- | ++ | + | +++ | --- | ANA, ASMA, anti SLA/LP, ANCA, ALKM-1 antibodies |
| |
Alcoholic hepatitis | +/- | + | - | + | - | AST>ALT | --- | --- |
| |
Drug induced hepatitis | +/- | + | - | + | + | ++ | --- | --- |
|
Treatment
Treatment of hepatitis A and hepatitis E is supportive as they are usually self-limited. Chronic hepatitis E is treated with the antiviral ribavirin.
Hepatitis B infection is treated with pegylated interferon alfa or nucleoside analogs (entecavir, tenofovir) based on the clinical picture including ALT and HBV DNA levels and presence or absence of cirrhosis.
Treatment is indicated in chronic Hepatitis C infection which is defined as the presence of detectable HCV RNA levels for 6 months. The selection of treatment regimen depends on viral genotype, presence or absence of cirrhosis and other patient factors. Some of the commonly used antiviral regimens include sofosbuvir-velpatasvir, glecaprevir-pibrentasvir and ledipasvir-sofosbuvir
Acute hepatitis D has no specific treatment. For chronic hepatitis D infection, treatment is indicated with PEG interferon alfa for patients with detectable HDV RNA, elevated ALT and evidence of active liver disease. Asymptomatic patients can be monitored for development of active disease.
Alcoholic hepatitis is generally treated with alcohol abstinence and supportive care in mild to moderate cases. Severe cases are treated with tapering courses of glucocorticoids.
Autoimmune hepatitis is treated with glucocorticoid mono therapy or combination of glucocorticoid with azathioprine. Treatment decision is based on symptom severity, laboratory and histologic findings.
Prevention
Hepatitis A
- Vaccination especially amongst high-risk individuals who were not vaccinated in childhood. These include IV drug users, Chronic liver disease patients, and Men who have sex with men (MSM).
- For individuals at risk of both HAV and HBV, the combined vaccine used as a 3-does series is administered.